Abstract
Cancer cachexia (CC), a debilitating syndrome characterized by the involuntary wasting of skeletal muscle and adipose tissue, significantly reduces treatment efficacy and increases mortality in lung cancer patients. A major hurdle in developing therapies is the discordance between rapid-growth preclinical models and the protracted course of human disease. This study introduces a novel, inducible, lung epithelial cell-specific $Kras^{G12D/+}$ (G12D) mouse model that phenocopies the mutational, transcriptomic, and metabolic characteristics of human lung CC. Our findings reveal that adipose tissue wasting is an early-onset event that precedes muscle loss and is driven by tumor-secreted factors promoting adipocyte lipolysis. This early wasting phenotype was validated in human patients using longitudinal data, suggesting that metabolic reprogramming of adipose tissue occurs well before clinical diagnosis.
Introduction
Cancer cachexia affects the majority of patients with advanced lung cancer, yet there are currently no FDA-approved treatments. The failure of many potential therapies in clinical trials is often attributed to the limitations of traditional preclinical models. Most studies rely on heterotopic models, such as injecting Lewis Lung Carcinoma cells into a mouse's flank, which results in explosive tumor growth (reaching 5-10% of body weight within days). This rapid progression fails to capture the months-long systemic metabolic shifts and the specific lung microenvironment seen in human patients. To bridge this gap, we developed a model that more accurately reflects the slow, systemic progression of lung cancer cachexia.
The G12D Mouse Model
We generated an inducible, lung epithelial cell-specific $Kras^{G12D/+}$ (G12D) mouse model. By using Tamoxifen to activate the oncogenic $Kras$ mutation specifically in the "club cells" of the lungs, we initiated a disease course that develops over a protracted 12-week period. Unlike rapid-growth models, the G12D mice experienced a gradual ~15% body weight loss, with 83% of the cohort eventually meeting the criteria for cachexia. This timeline allows for the observation of early metabolic changes that are often missed in accelerated models.
Early Adipose Wasting vs. Muscle Loss
The most significant insight from the G12D model is the temporal separation of fat and muscle wasting. At the 6-week mark—halfway through the study—the mice exhibited a reduction in fat pad weights of over 50%, despite the tumor burden being minimal (less than 1% of total body weight). In contrast, skeletal muscle remained largely intact until the 12-week mark.
This "adipose-first" phenotype suggests that fat loss is not merely a late-stage consequence of end-stage disease, but an early, systemic metabolic event. Furthermore, the mechanism of fat loss in this model is driven by lipolysis—the active breakdown of fats into glycerol and fatty acids—rather than "beiging" (the conversion of white fat to heat-generating brown fat), which is frequently cited in other cachexia models.
Tumor-Host Communication
To investigate the cause of this early lipolysis, we utilized 3D lung tumor organoids. By treating healthy fat cells in vitro with the conditioned media (secreted fluids) from these organoids, we observed a direct trigger for fat breakdown. While GDF-15 was identified as a potential signaling molecule, the research suggests that a complex "cocktail" of tumor-released factors is likely responsible for the systemic metabolic reprogramming. Notably, neutralizing IL-6 did not halt the lipolysis in these experiments, indicating that the pathways involved are distinct from some previously studied cachexia mechanisms.
Clinical Validation in Human Cohorts
To ensure these findings were relevant to human health, we performed a secondary analysis of the National Lung Screening Trial (NLST). Using AI-based tools to analyze body composition from CT scans taken years before and at the time of cancer diagnosis, we found a striking parallel. Human patients (particularly females) diagnosed with stage 3-4 lung cancer showed a significant reduction in visceral adipose tissue (VAT) area and density in the years leading up to their diagnosis ($P=0.03$). This confirms that early fat loss is a clinically relevant feature of the human disease trajectory.
Conclusion and Future Directions
The G12D mouse model provides a more faithful representation of human lung cancer cachexia, highlighting early adipose tissue wasting as a critical metabolic milestone. This research shifts the focus toward early intervention and the identification of tumor-secreted factors that drive lipolysis.
Future work will need to address the role of metastasis, which often accelerates cachexia, and further investigate the sex-specific differences observed in human VAT and SAT (subcutaneous adipose tissue) loss. Identifying the specific "smoking gun" molecule responsible for this early lipolysis remains a priority for developing targeted therapies to prevent the onset of wasting in lung cancer patients.
Summary updated